Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed stage III or IV ovarian epithelial cancer or primary peritoneal cavity cancer meeting 1 of the following criteria: * Progressive\* or persistent\* disease during or after primary chemotherapy * Recurrent disease \< 6 months after completion of primary therapy that had resulted in a complete response * Persistent\* or recurrent disease after second-line or additional therapies NOTE: \*Progression or persistence can be based on serological (CA 125 \> 100 U/mL OR 2 times baseline), radiographic (measurable or evaluable disease), or second-look surgical findings * Tumor expressing NY-ESO-1 determined by IHC or RT-PCR * HLA type expressing DPB\*0401, DPB1\*0201, DRB1\*07 * No CNS metastases PATIENT CHARACTERISTICS: Age * 18 to 75 Performance status * Karnofsky 70-100% Life expectancy * More than 16 weeks Hematopoietic * Not specified Hepatic * Not specified Renal * Creatinine ≤ 2.0 mg/dL Cardiovascular * No congestive heart failure\* * No clinically significant hypotension\* * No symptoms of coronary artery disease\* * No cardiac arrhythmias on EKG requiring drug therapy\* * No history of cardiovascular disease\* * No other significant cardiovascular abnormalities\* NOTE: \*Patients with any of the above undergo a stress test and/or echocardiography before being determined ineligible for study participation Pulmonary * FEV\_1 ≥ 60% of predicted\* * DLCO ≥ 55%\* NOTE: \*Patients with clinically significant pulmonary dysfunction only Other * Not pregnant or nursing * Fertile patients must use effective contraception * HIV negative * No active infection * No oral temperature \> 38.2°C within the past 72 hours * No systemic infection requiring chronic maintenance or suppressive therapy PRIOR CONCURRENT THERAPY: Biologic therapy * No other concurrent immunotherapy (e.g., interleukins, interferons, vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy) Chemotherapy * See Disease Characteristics * At least 3 weeks since prior standard or experimental chemotherapy Endocrine therapy * No concurrent systemic corticosteroids except for treatment-related toxicity Radiotherapy * At least 3 weeks since prior radiotherapy Surgery * See Disease Characteristics Other * At least 3 weeks since prior immunosuppressive therapy * More than 3 weeks since prior investigational drugs and recovered * No other concurrent investigational agents * No concurrent pentoxifylline